[A20-69] Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V
Last updated 04.02.2021
Project no.:
A20-69
Commission:
Commission awarded on 07.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Indication:
| Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year |
Result of dossier assessment:
| No statistically significant differences in any outcome; added benefit not proven |
| Project no. | Title | Status |
|---|---|---|
| A20-125 | Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69 | Commission completed |
Federal Joint Committee (G-BA)
2021-02-04: A G-BA decision was published.